Regulator orders drugmaker Valeant management to cease trading
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Moody's Downgrades Valeant Pharma (VRX) to 'B2'; Ratings Remain on Review for Further Downgrade
March 31, 2016 3:08 PM EDTMoody's Investors Service downgraded certain ratings of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and subsidiaries, including the Corporate Family Rating to B2 from B1, the Probability of Default Rating to Caa1-PD from B1-PD and the senior unsecured rating to B3 (LGD 3) from B2 (LGD 5). There is no action today on Valeant's Ba2 (LGD 2) senior secured rating, which remains under review for downgrade. All of these ratings remain under review for further downgrade, related to Valeant's late 10-K filing, continuing a rating review initiated on February 29, 2016. Moody's also affirmed Valeant's Speculative Grade... More
